MarketPulse
T

$TAK

5 articles found
2 positive
1 negative
2 neutral
BenzingaBenzinga··Vandana Singh

Eli Lilly Surges on China Expansion Despite Supreme Court Lawsuit Setback

Eli Lilly announces $3B China investment and Mounjaro reimbursement win, but faces multibillion-dollar lawsuit over Actos disclosures.
LLYAAPLTAKclass action lawsuitMounjaro
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Feiba VH Market Poised for Steady Growth Through 2035 on Rising Hemophilia Cases

Feiba VH market projected to grow through 2035 driven by rising hemophilia diagnoses, healthcare spending, and surgical procedures. North America leads; Asia-Pacific fastest-growing.
TAKAsia-Pacificmarket growth
BenzingaBenzinga··Vandana Singh

Takeda Stock Falls Despite Positive Pediatric UC Data for Entyvio

Takeda stock fell 0.64% despite positive Phase 3 results for Entyvio in pediatric ulcerative colitis, with 47.3% of patients achieving clinical remission.
TAKPhase 3 trialpharmaceutical
GlobeNewswire Inc.GlobeNewswire Inc.··Sns Insider

Blood Plasma Derivatives Market to Double to $104B by 2033 on Rising Disease Prevalence

Blood plasma derivatives market to double to $104B by 2033, driven by rising disease prevalence and immunoglobulin demand across developed and emerging markets.
BAYRYTAKGRFSBAXmarket growthAsia-Pacific expansion
BenzingaBenzinga··Vandana Singh

J&J Receives FDA Breakthrough Designation for Rybrevant Faspro in HPV-Negative Head and Neck Cancer

FDA grants J&J's Rybrevant Faspro breakthrough designation for HPV-negative head and neck cancer, potentially accelerating patient access to this new treatment option.
JNJMRKSNYTAKICLRclinical trialimmunotherapy